Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 41Sarcoma 1Classical hematology 1CNS 1

Conditions

Central Nervous System Neoplasms 36Neuroblastoma 35Brain Neoplasms 25Medulloblastoma 22Astrocytoma 10Glioma 8Glioblastoma 7Choroid Plexus Neoplasms 7Rhabdoid Tumor 6Oligodendroglioma 6Neuroectodermal Tumors, Primitive 6Ependymoma 6Breast Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Neoplasms 5Ganglioneuroblastoma 5Esthesioneuroblastoma, Olfactory 5Carcinoma, Non-Small-Cell Lung 5Testicular Neoplasms 4Testicular Germ Cell Tumor 4Small Cell Lung Carcinoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Gliosarcoma 4Thyroid Neoplasms 3Teratoma 3Squamous Cell Carcinoma of Head and Neck 3Seminoma 3Endodermal Sinus Tumor 3

Interventions

fludarabine phosphate 1anlotinib 1aflutinib 1Temozolomide 1Specimen Handling 1Radiotherapy 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Interleukin-13 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Cyclophosphamide 1Cisplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Cisplatin × CNS × Clear all
NCT01578668 2015-01-26

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Guangzhou Medical University

Phase 2 Completed
69 enrolled
CNSThoracic

Adenocarcinoma of Lung, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡